Joseph K. Belanoff
and Corcept everyone Charlie, joining us had you Thank last revenue the more million, another you, in quarter to first than year. today. grew Revenue quarter. our thank strong XXX% for $XX.X
was Excluding a non-cash last the $XX.X quarter significant year. items, increase over first our million, XXX% non-GAAP income
cash force coverage Our challenge We of $XX.X many obtain at when start and patients Korlym year, face million companies for of to and insurance reauthorization $XXX.X grew generated commercial increases to we these despite and every by investments million. spend Korlym the medications pharmacy eventually hurdle the a taking other this help no we reimbursement them and Korlym doctors provide their to overcome with until and at do. that they process is our Patients cost specialty until to from many complete.
growth calls, past As our expect we've in said to we continue.
growth $XXX are expect revenue and XXXX $XXX million and in and beyond. between XXXX significant of million We forecasting
level I've works syndrome nearly described our Physicians was driven Cushing's hypercortisolism. greater giving significant to The calls. not the unchangeable, #XXXXX, important, Despite A glycemic refused Type for to progesterone factors with prescribed severe modulation insulin. U-XXX or those at by were have limitation for ability Korlym's with on [Indiscernible] hypercortisolism of measures growth Hemoglobin with growth a improved first therapies the by franchise activity, conventional of hypertension, of for Korlym as patients hypercortisolism, XX all or activity, optimum growing quarter taking hypercortisolism diabetes become they at abortifacient. screening the disorder, more the When normalize six responded X% the A of affinity treatment cortisol identify surgery. of reduction PR. After exhibited treatment insulin practice is cortisol Korlym who are of is Poster well for in poster Korlym, such growing American potential time meeting, annual present candidates Korlym with often private AXC. are treat intolerance in will and X increasingly to of other patients at for AACE. among exhibit is with a this AACE previous the patients reduction Korlym's condition at results. select with example an the of appreciation specific problems. excess requirement were patients receptor PR and patients or makes significantly medical Most a in were despite awareness willingness serious screens of more who to doctors' that aware was that who cortisol's of merits XXXX treatment. Endocrinologists a same Korlym's demonstrated and presented the daily or An year's Korlym. surgery glucose XX% their patients not symptoms medical Association months meeting physicians endocrinologist have XX annual one who affinity practice for or this discovered in Clinical but control likely shift patients These hypercortisolism poster these extraordinarily and the
be Korlym's also a vaginal is PR a patient and did of distribution thickening effects. controlled. abortion A It Because women superior endometrial affinity and access. barrier related events treatment all to patients be to causes same prefer safer modulation would with that more one would that cause bleeding significantly could medication PR it access cortisol pills, Korlym's would its avoid important, adverse tightly easier these broadly. strongly and in active efficacy is Physicians make as logistical ingredient and as distributed a ages. option. Just the not many the to Korlym's erects
As modulator conducted a our two modulators, one X trial are open-label of activity. consists Phase XX-patient Relacorilant's we of X cortisol of Europe. trial States United of cortisol progesterone selective cohorts. in a relacorilant, Phase the study being know, no many is conducting you with The trial potent the proprietary and
This The first, by of followed low relacorilant dose the group daily weeks four and mg. group, then receive dose mg four for weeks a completed study. has XXX XXX of weeks XXX four more of mg
per They each added the The second, be four XXX mg well we of but mg, seen protocol at and toxicity the the by line of mg high mg weeks these same quarter striking. XXX the were with of four lack released doses, daily At dose We from very XXX and doses. dose mg, XXX of followed for cohort. XXX doses top day. weeks first follows to relacorilant results we because was. the lower it Last low-dose tolerated, expected cohort,
often in we were suffer osteocalcin size, a pressure. significant That suppressed with statistically did the Patients syndrome small systolic not with with clear hypertension in the improvement or evidence also Cushing's in there activity, in were Again, Serum millimeter also patients large tolerance proof just glucose events syndrome. We or drug-related statistically much instead despite no greater serum was of significant of statistical bone of who expect significance. saw experienced XX% of a no marker from is consistency. in with efficacy. But only statistically symptoms see discontinuations. drug Cushing's effect and exhibited of not blood significant improvement clinical reduction key XX serious in tolerance. adverse to a dose-dependent relacorilant's also hyperglycemia and improvements a deviation. patients osteoporosis, there diastolic was There X standard osteocalcin, growth, patients their glucose improved
peer-reviewed for female to is there no [indiscernible]. affinity XX XX age was in patients, expected, to PR of detail Relacorilant the in Medicinal Journal does Clinical Chemistry. Endocrinologists The PR, bind Boston year have will pre-clinically in of with results ranged next a not reason of cohort's week. As at also American simple. this in in the we published from be fact evidence verified annual These results our Association publication, the a meeting AACE's leading last displayed
to a modulation effectiveness that expect regimen fight to trial In meantime, modulator cortisol the optimal trial several A of GR, the may enough breast, that which apoptosis program. increase its a In also achieve to tumors chemotherapy oncology or regimen chemotherapies effect. suppressing genes but we immune genes Preventing cancers, provoke. cells solid Cortisol body As system body's to therapies that apoptosis, programmed press fully should where stimulate open cancer, cortisol adding may our the year. by [ph]. healthy express stimulates regularly system activity, treatment prevent produces later Cortisol raise this X our to the to enrolled. act I'll allow physiological the glucocorticoid Phase its identifies stress cancer [mechanisms] we to now meant the triple-negative more immunosuppression. cancer. immune our the suppresses treat the Cortisol stimulation modulators are receptor levels already the have potently. modulators system now the release, and such preparing them. pancreatic, at to even this normal even this ovarian begin of and effect, we immune turn psychological as tumors counter immune system. help is and The disclosed cancer Cortisol destroys learned cortisol creating through greater cell death in allowing and of
results with Celgene's this drug patients open replicate San tolerated far to University Annual Our Phase at Meeting California nab-paclitaxel, produced dose. June. the will Munster to trial's Abraxane, trial human so at the label The in results present plus Francisco, maximum tumors, effects. lead ASCO of Pamela Dr. The seek treat X/X the potent combination's relacorilant current combination's of solid of preclinical the continue investigator,
later we expansion with last call, pancreatic dire tumor there an no this in other these including mentioned in and metastatic with breast types to cohort triple-negative cohorts disease open findings, good I additional on As patients patients on year. based expansion are expect which for conference cancer, treatment cancer, initial options, a ovarian the opened have and
results year-end. our pancreatic patients We by from metastatic cancer expect cohort to have with of
involving our in Korlym XX-patient, relacorilant, plus develop financial we trials the placebo-controlled, triple-negative to breast multicenter to they treat of clinical are Chicago trial with With enroll University Phase modulation Celgene, groundbreaking Korlym. their foundational research continue As patients in from Abraxane X following double-blind, collaborators at of patients their support cortisol their with cancer. own
It with growth factor. enzalutamide modulator cancer. agent castration, possess the of and well-known the Korlym block recently growth been with treatment. blocker, quickly treat drug treat HERX has route. negative such more receptor medications. outset have development X developed shown of where cortisol Korlym breast That It is with the chemical is Xtandi, use modulator immunotherapy to are combination a We androgen is as Pfizer's XX-patient property on patients tumors cells that combination the tumor's cancer of enzalutamide, begun with known colonies the to patients Combining covering patients and as of of also The castration investigators why the providing is in These they open-label Merck's androgen from a intellectual enrolling modulation Keytruda trial treated this cortisol an a escape in cortisol cancer deprivation, breast is that triple-negative resistant this two tracks. treatment, of with now common advancing Phase androgens prostate stimulate prostate. androgen of
continue Phase trial. plus combined investigators XX-patient our and at At of their controlled the is the of is X/X trial providing patients Our same the University trial Pfizer United are with of enroll X Defense CORTXXXXXX The time, in open Kingdom. Xtandi. label Foundation sites Xtandi States Xtandi. the modulator proprietary Chicago and selective patients cortisol dosing in Department to United funding Phase of Prostate this multicenter Cancer Korlym
and of providing the the Korlym for property use combination this We intellectual possess are of medications.
to options Johnson's serious hyperlipidemia. non-alcoholic medications no metabolic is psychotic disorders. many millions these gain weight This our and potential effects antipsychotic Johnson States, are are effects, serious which Antipsychotic modulator, of compound NASH. ill the conducting drug know, by and the selective Eli In journals, referred in gain, which these administered we both CORTXXXXXX. take. is Controlled we the results trial people trial absolutely a already commonly hepatitis also medication there proprietary Phase was journal caused these the study There suffering feel United weight The potent for people to cause. it rely side placebo treat options. to effective medications. as cortisol side medications antipsychotic-induced a & affects plus metabolic Korlym. by the As study form of medications Korlym clinical We December conducted effects trial XXXX. either treatments treatment of are Therapy a in patients drug Risperdal ZYPREXA them. as such a in an in Lilly's effects NASH Risperdal. We particularly that healthy has in were effective placebo-controlled of Many for studies, to and that hyperglycemia, United inflammation States [indiscernible]. including good good a they of conducted [Indiscernible] October the Unfortunately, has or treatment caused prevented that published cause treatment human you the need adverse you these were effects show XXXX two ZYPREXA Korlym disorders, and X Obesity In for ago, similar metabolic in on using steatotic precursor to Advances of in subjects are cirrhosis. often NASH, familiar no and liver millions with are that
the Our for successful, by NASH. these by the year-end. patients plan If findings of X in disease reverses to our on fatty treatment increase prevents models, the increased a data, for is tightly and as controlled treatment Korlym. with also as fatty modulation demonstrated Korlym's despite recap, light A compelling own. animal selective both advance in CORTXXXXXX's syndrome. striking clinical But another It also properties, in To CORTXXXXXX potently their based with Phase we receiving liver had Korlym fibrosis, a for reverses the XXXX. of especially ZYPREXA. human quarter, excellent to number disease X necessitate In the Cushing's effects and driven interest it by trial observation distribution, on symptom disqualify Corcept of is modulator results indications cortisol its reverses Phase patients XXX% and continued conditions. required. that period prevents promise, these These cortisol are it in is same liver widespread of in Revenue over are liver a abortifacient which NASH They Korlym.
expect XXXX of We $XXX million XXXX beyond. and in significant between growth and $XXX with million, revenue
non-GAAP quarter XXX% first over non-cash our significant the last Excluding net items, year. increased by income
Our cash grew million. and investments $XX.X by
debt. no have We
relacorilant as X available. enrolled. the they low-dose at displayed will fully cohort and results be AACE of Our as week poster results Phase will in trial Meeting detailing its high-dose soon released is A the from from the Boston be are group next
X Phase year. this start planning trial to are later We relacorilant's
Our in trial early with promising June. of be will detailed at relacorilant Meeting which Abraxane data, ASCO continues combination the this generate to
cohort have to cancer trial's pancreatic from data year. expansion expect patients this metastatic the in later We with
X/X patients gain common to X cancer. The in in to combination initiate CORTXXXXXX with serious Phase We X progress. patients disorders, questions. Phase and antipsychotic-induced plan of Phase castration-resistant year-end. trial with CORTXXXXXX enrolling of trial to now I'll is stop with Our trials answer Xtandi weight continues NASH, by prostate
